Breaking News

pHOXBIO Unveils Trial Results from COVID Prophylactic Nasal Spray

According to the study, the novel prophylactic nasal spray prevented infection from SARS-CoV-2, the virus that causes COVID-19.

Author Image

By: Charlie Sternberg

Associate Editor

pHOXBIO Ltd. has shared results from a randomized, double-blind, placebo-controlled clinical trial which demonstrate that pHOXWELL, its novel prophylactic nasal spray, prevented infection from SARS-CoV-2, the virus that causes COVID-19. In a pivotal Phase 2/3 clinical study, there were 63% fewer SARS-CoV-2 infections in high-risk healthcare workers given pHOXWELL compared to placebo (p=<0.0001).   About pHOXWELL   pHOXWELL is a self-administered prophylactic nasal spray designed to of...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters